GC1008

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

GliomaIdiopathic Pulmonary FibrosisMalignant Pleural MesotheliomaFocal Segmental Glomerulosclerosis

394 competitors in Glioma

#DrugCompanyPhaseTrials

1

Paraplatin

AAvyxa

Phase 3

152

Trexall

Alnylam Pharmaceuticals

Phase 3

23

Bicnu

MMelissa K Accordino

Phase 3

74

Photofrin

PPinnacle Biologics Inc.

Phase 3

25

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

16

Modeyso

CChimerix

Phase 3

37

Selumetinib /m2

NNational Cancer Institute (NCI)

Phase 3

18

Luvometinib

SShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 3

19

Chemotherapeutic Agent

Day One Biopharmaceuticals

Phase 3

110

IFN-α

PPeking University People's Hospital

Phase 3

1Show 23 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Idiopathic Pulmonary Fibrosis1 trial

Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Completed·Sanofi·Phase 1·NCT00125385·25 enrolled

Glioma1 trial

Safety and Imaging Study of GC1008 in Glioma

Completed·UUniversity Medical Center Groningen·Phase 2·NCT01472731·12 enrolled

Focal Segmental Glomerulosclerosis1 trial

Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS

Completed·Sanofi·Phase 1·NCT00464321·16 enrolled

Malignant Pleural Mesothelioma1 trial

Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma

Completed·—·Phase 2·NCT01112293·14 enrolled

Details

Drug Info

Related News